Welcome to our dedicated page for Janux Therapeutics SEC filings (Ticker: JANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Janux Therapeutics, Inc. (Nasdaq: JANX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including current reports on Form 8-K and other periodic filings. As a clinical-stage biopharmaceutical company focused on tumor-activated immunotherapies, Janux uses these filings to report financial results, business updates and certain corporate events.
Form 8-K filings for Janux include items such as the public release of quarterly financial results under Item 2.02, where the company furnishes press releases summarizing collaboration revenue, research and development expenses, general and administrative expenses, and net loss for specific reporting periods. Other 8-Ks address corporate matters under Item 5.02, such as changes in executive roles or departures of certain officers, along with references to relevant compensation or severance arrangements.
For investors analyzing JANX, the full SEC record also encompasses annual reports on Form 10-K, quarterly reports on Form 10-Q, and any registration statements or proxy materials the company may file. These documents typically provide details on the TRACTr, TRACIr and ARM platforms, risk factors related to clinical development, descriptions of the JANX007 and JANX008 clinical programs, and information on collaborations, including the TRACTr agreement with Merck.
On Stock Titan, Janux filings are updated as new documents are posted to EDGAR, and each entry can be paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to earnings, pipeline updates, or corporate governance, and can review the underlying text when deeper due diligence is required. This page also provides a convenient route to track any future insider transaction reports on Form 4, as well as proxy statements that may discuss executive compensation and governance policies.
JANX notice of proposed sale of Common Stock under Section 144 related procedures. The submission lists 71,016 shares tied to an exercise of options under a registered plan dated 04/02/2026 and 3,786 shares from restricted stock vesting dated 01/01/2026. The excerpt also records a 2,714-share sale on 01/02/2026 generating $37,263.22.
Janux Therapeutics files its annual report describing a clinical‑stage pipeline built on proprietary TRACTr, TRACIr and ARM platforms for oncology and autoimmune diseases. The company focuses on tumor‑activated T‑cell engagers designed to reduce cytokine release syndrome, limit healthy‑tissue toxicity and extend half‑life.
Lead programs include PSMA‑targeted JANX007 for metastatic castration‑resistant prostate cancer, EGFR‑targeted JANX008 for solid tumors, and CD19‑targeted JANX011 for autoimmune indications. Janux also highlights collaborations with Merck and Bristol Myers Squibb and reports approximately $1.1 billion non‑affiliate market value and 60,831,656 shares outstanding.
Janux Therapeutics filed an 8-K to share fourth-quarter and full-year 2025 results and a business update. The company ended December 31, 2025 with $966.6 million in cash, cash equivalents and short-term investments, down from $1.03 billion a year earlier, providing substantial funding for its pipeline.
Research and development expenses rose to $125.9 million in 2025 from $68.4 million in 2024, while general and administrative expenses were roughly flat at $41.8 million versus $41.0 million. Net loss widened to $157.7 million from $69.0 million, reflecting heavier investment in clinical programs.
Operationally, Janux highlighted continued progress for TRACTr candidates JANX007 in metastatic castration-resistant prostate cancer and JANX008 in solid tumors, as well as the Phase 1 start of JANX011 in healthy volunteers. The company also announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb, including $50 million in upfront and near-term milestone payments and the potential for approximately $800 million in additional milestones plus tiered royalties.
Janus Henderson Group plc reported beneficial ownership of 5,350,453 shares of Janux Therapeutics, Inc. common stock, representing 8.9% of the class. The shares are held through various affiliated asset managers that exercise shared voting and investment power on behalf of their client accounts.
The filing explains that these asset managers manage multiple managed portfolios, such as funds and separate accounts, which actually receive all dividends and sale proceeds from the Janux shares. None of the individual managed portfolios owns more than 5% of Janux’s outstanding common stock.
State Street Corporation has filed a Schedule 13G reporting a passive ownership stake in Janux Therapeutics, Inc. common stock. As of 12/31/2025, State Street reports beneficial ownership of 3,853,951 shares, representing 6.4% of the outstanding common stock.
The filing shows shared voting power over 3,749,880 shares and shared dispositive power over 3,853,951 shares, with no sole voting or dispositive power. State Street certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Janux.
Janux Therapeutics, Inc. had a significant shareholder position reported in its common stock. A group of related Prosight entities and individual investor W. Lawrence Hawkins together reported beneficial ownership of up to 3,157,220 shares of Janux common stock.
Based on 60,147,807 shares outstanding as of November 4, 2025, Hawkins’ holdings represent about 5.3% of the company’s common stock
Janux Therapeutics, Inc. reported an equity compensation grant to its Chief Medical Officer, William Go. On February 2, 2026, he received 44,000 shares of common stock in the form of restricted stock units that vest in four equal annual installments beginning February 1, 2027.
He was also granted a stock option for 154,000 shares of common stock at an exercise price of $13.99 per share. Twenty-five percent of this option vests on February 26, 2027, with the remaining shares vesting in equal monthly installments over the following three years. Both holdings are reported as directly owned.
Janux Therapeutics, Inc. Chief Medical Officer William Go filed an initial ownership report on Form 3. The filing states that no Janux common stock or derivative securities are beneficially owned. This establishes his baseline insider ownership position as zero under SEC reporting rules.
Janux Therapeutics shareholder plans a sizable stock sale. A person identified as Andy Meyer has filed to sell 178,767 shares of JANX common stock through Morgan Stanley Smith Barney LLC on or around 01/26/2026 on the NASDAQ. The filing lists an aggregate market value of $2,601,113.48 for these shares, with 60,147,807 shares of common stock outstanding. The shares to be sold were acquired on 01/26/2026 by exercising options under a registered plan for cash. Over the prior three months, the same seller reported multiple JANX stock sales totaling several tranches, including 118,122 shares on 01/23/2026 and 16,665 shares on 10/28/2025.
JANX insider Andy Meyer filed a notice of proposed sale under Rule 144 to sell 118,122 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,738,389.66 and 60,147,807 shares outstanding.
The shares were acquired on 01/23/2026 by exercising options under a registered plan and paid for in cash on the same date. In the past three months, Meyer has sold additional JANX common shares, including 16,665 shares on 10/28/2025 for gross proceeds of $500,314.00, under separate transactions.